Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2024)
20 slides from Biotron's shareholder meeting presentation, Nov 28, 2024
Slide 1: Presentation to Annual General Meeting
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 November 2024 The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000 (20 pages by email) For personal use only Dear Madam, PRESENTATION
Slide 2: Chairman's Address to the AGM
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 November 2024 CHAIRMAN’S ADDRESS TO THE AGM Again, welcome ladies and gentlemen. For personal use only At last year’s AGM we discussed, at length,
Slide 3: Chairman's Address (continued)
It is my intention to now move to the business of the meeting after which I shall invite our CEO, Michelle Miller, to deliver the Managing Director’s report. We will allow as much time as is needed for questions. Sincerely Michael J. Hoy For personal use only Chairman
Slide 4: Annual General Meeting November 2024
For personal use only ANNUAL GENERAL MEETING ASX:BIT 28 November 2024
Slide 5: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 6: Industry-leading experts focused on transformative viral treatments
Industry-leading experts focused on transformative viral treatments For personal use only Experienced Board & Management team with pharma, finance and VC backgrounds Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large internatio
Slide 7: 2024 in Review
2024 in Review For personal use only - Readout of the results from three Phase 2 clinical trials - This is a remarkable achievement for any organisation in a relatively short period of time - Progressed early-stage programs - Hepatitis B virus - Dengue virus - Progressed next-generation drugs for HI
Slide 8: BIT225-010 and -011 Phase 2 HIV Clinical Trials Met Primary End Points
BIT225-010 and -011 Phase 2 HIV Clinical Trials Met Primary End Points For personal use only 01 02 03 Results from these two Unique mechanism that Implications go beyond the trials further our combines Company’s HIV Program understanding of BIT225 immunomodulation combined with direct acting • The r
Slide 9: Why HIV-1?
Why HIV-1? The increased prevalence of HIV-1 infections, % of patients on treatment due to improved For personal use only disease awareness and the need for treatments to improve quality of life are ~38.4m people expected to drive market growth to over globally living with US$50b by 2030 HIV despite
Slide 10: BIT225-010: Phase 2 Trial Overview
BIT225-010: Phase 2 Trial in Naïve, Acutely Infected HIV Population - OVERVIEW For personal use only BIT225 or placebo added to cART in HIV-positive individuals commencing cART treatment (n=27, randomised 2:1) BIT225/cART or placebo/cART dosing continued for 24 weeks. At conclusion, everyone continu
Slide 11: BIT225-010: Outcomes vs Objectives
BIT225-010: Phase 2 Trial in Naïve, Acutely Infected HIV Population – OUTCOMES vs OBJECTIVES For personal use only PRIMARY OBJECTIVES OUTCOMES 1. Safety and tolerability - Safe and generally well tolerated - No deaths or drug-related SAEs - AEs were similar to those seen in previous trials 2. Impact
Slide 12: BIT225-010 Reduction in Viral Loads Are Faster in BIT225 Group
BIT225-010 HIV-1 Phase 2 Trial – Reduction in Viral Loads Are Faster in BIT225 Group For personal use only - BIT225-treated cleared virus faster than those on ART alone - 72% of BIT225/ART group vs 33% of placebo/ART reached limited of detection by day 28 - Rate of decline of virus levels in critica
Slide 13: BIT225-010 HIV-1 Phase 2 Trial – Conclusions
BIT225-010 HIV-1 Phase 2 Trial – Conclusions For personal use only • The changes seen when BIT225 is added indicate that the drug has induced statistically significant changes in specific immune cell populations, markers, and cytokines. • The immune results are consistent with those seen in earlier
Slide 14: BIT225-011: Phase 2 Trial in Treatment-Experienced Immune Non-Responders
BIT225-011: Phase 2 Trial in Treatment-Experienced Immune Non-Responders For personal use only First time BIT225 has been trialed in this at-risk HIV population. Trial was run at sites in Sydney, Australia 20 participants cART cART + BIT225 cART Screening Observation Period Treatment Period Follow-u
Slide 15: BIT225-011: Outcomes vs Objectives
BIT225-011: Phase 2 Trial in Treatment-Experienced Immune Non-Responders – OUTCOMES vs OBJECTIVES For personal use only PRIMARY OBJECTIVES OUTCOMES 1. Safety and tolerability Safe and generally well tolerated No deaths or drug-related SAEs AEs were similar to those seen in previous trials 2. Viral m
Slide 16: COVID-19 Clinical Program
COVID-19 Clinical Program For personal use only In 2022 BIT's lead antiviral drug was shown to: • Prevent COVID-19, • Reduce virus levels, and • Stop the cytokine storm in a relevant, robust, industry- recognised animal model of disease As BIT225 had been tested in humans for other viral diseases it
Slide 17: BIT225-012: Phase 2 COVID-19 Clinical Trial
BIT225-012: Phase 2 COVID-19 Clinical Trial PRIMARY OBJECTIVES OUTCOMES For personal use only 1. Safety and tolerability - Safe and generally well tolerated - No deaths or drug-related SAEs - AEs were similar to those seen in previous trials 2. Efficacy assessed by nasal viral loads No statistically
Slide 18: Early-Stage Antiviral Programs
EARLY-STAGE ANTIVIRAL PROGRAMS For personal use only • Biotron remains focused on its platform of viroporin antagonists which uniquely combine direct-acting antiviral and immunomodulatory activities across numerous viruses responsible for important human disease. • The results from BIT225 have impor
Slide 19: Summary
SUMMARY - Preliminary analyses indicate that both HIV trials achieved their primary objectives - The data supports previous findings that BIT225 uniquely combines direct-acting antiviral and For personal use only immunomodulatory activities - The challenge for HIV therapies is demonstrating clinical
Slide 20: Biotron Limited contact
For personal use only BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329